Norges Bank
GEVA

Norges Bank’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Norges Bank’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-201,582
Closed -$19.7M – 2351
2015
Q1 		$19.7M Sell
201,582
-3,683
-2% -$390K 0.01% 1219
2014
Q4 		$19M Buy
205,265
+14,676
+8% +$1.16M 0.01% 1244
2014
Q3 		$13.1M Sell
190,589
-263,813
-58% -$18.9M 0.01% 1417
2014
Q2 		$47.6M Buy
454,402
+227,201
+100% +$19.3M 0.01% 1060
2014
Q1 		$18.9M Buy
227,201
+35,000
+18% +$3.24M 0.01% 1182
2013
Q4 		$12.4M Hold
192,201
– – 0.01% 1451
2013
Q3 		$12.2M Buy
192,201
+87,321
+83% +$4.3M 0.01% 1444
2013
Q2 		$4.41M Buy
+104,880
New +$4.78M ﹤0.01% 1903

Norges Bank's GEVA Position: Q2 2015 in Review

Norges Bank sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 201,582 shares — an estimated $19.7M sold.

Norges Bank first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $47.6M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Norges Bank reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Norges Bank sold 201,582 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $19.7M.
  • Norges Bank first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Norges Bank's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $47.6M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Norges Bank's 13F filing for Q2 2015, filed 10 Aug 2015.